Sensei Biotherapeutics, Inc. (SNSE)
NASDAQ: SNSE · Real-Time Price · USD
0.606
-0.004 (-0.69%)
At close: Aug 30, 2024, 4:00 PM
0.595
-0.011 (-1.75%)
After-hours: Aug 30, 2024, 4:21 PM EDT
Sensei Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
15.24M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cutera | 169.19M |
STRATA Skin Sciences | 32.73M |
Syra Health | 7.07M |
Immuron | 2.44M |
Can-Fite BioPharma | 743.00K |
Aptorum Group | 431.38K |
SNSE News
- 25 days ago - Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 3 months ago - Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 - GlobeNewsWire
- 4 months ago - EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member - Business Wire
- 4 months ago - Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 months ago - Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting - GlobeNewsWire
- 5 months ago - Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference - GlobeNewsWire
- 5 months ago - Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment - GlobeNewsWire